Paragraph with Menu

How can you help our CDG community? It is easy! Share among your social media and other channels the information we make available within this section and website. This raises awareness, accelerates diagnosis, and secures better care and management for our CDG children and adults!

Our community is in a relentless pursuit of therapies! 

Nutritional replacement therapies for CDG 

 

Ribitol is considered for the following CDG types: 

  • ISPD-CDG (more information about this specific CDG type HERE, HERE)
  • FKRP-CDG (more information about this specific CDG type HERE and HERE)

About ISPD-CDG: is caused by mutations in the ISPD gene. Defects in ISPD lead to impaired α-dystroglycan (α-DG) O-mannosylation.

About FKRP-CDG: Mutation in the FKRP gene can also cause a severe congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies and a congenital muscular dystrophy-dystroglycanopathy with or without impaired intellectual development.

Paragraph without Menu

What is Ribitol? 

Our body cells have an outer membrane made of fats, proteins and sugars. 

Ribitol is a sugar necessary for the function of specific structures that are located in the cell membrane. These structures are mainly found in muscles, eyes and brain. 

How can ribitol supplementation help people living with ISPD-CDG?

Oral administration of ribitol showed benefits in cardiac and skeletal muscle of a mouse model. 

Treatment of ISPD-CDG patient’s cells with ribitol improved  glycosylation and restored the normal shape of the cells. Further studies are needed to assess the effect of this sugar in patients. 

How can  ribitol supplementation help people living with FKRP-CDG?

The Fukutin-related protein  (FKRP) is responsible for modifying the sugar ribitol so it can be added to certain sugar trees (glycans) that decorate a protein called alpha (α)-dystroglycan. This protein helps stabilize and protect muscle fibers and also helps direct the movement (migration) of nerve cells (neurons) during early development. 

Ribitol supplementation was tested in a FKRP-CDG mouse model, improving skeletal and respiratory functions as well as reducing cardiac fibrosis (abnormal thickening of the heart valves).   

 

Publications in CDG are constantly growing. We  have selected articles of special interest for you, see below. Not all are open access, thus if you wish to  access the full information, please contact us at https://worldcdg.org/contact

Keep in mind, you are not alone. Though Congenital Disorders of Glycosylation (CDG) are categorized as “rare” there is an amazing community at your fingertips working day and night to improve the lives of many people living with CDG and their family members. We want you to know everything that is available about therapies in lay language, but we suggest you enter into it at your own pace and comfort level.

We are here to help
Should you need more details please do get in touch with our Team

Ensure that you are up to date, and join our mailing list:

 Subscribe our World CDG magazine

For further learning about CDG, move ahead to our community tailored sections across https://worldcdg.org/  

 

Didn't find what you are looking for?

Your question may help others

Authors

Vanessa Ferreira and Sandra Brasil (CDG & Allies FCT, NOVA University, World CDG Organization and Portuguese Association for CDG).  Ines Santos, Tiago Martins, Madalena Raposo from Sci and Volunteer Program Nova School of Science and Technology 2021. Ana Sofia Rodrigues (content management, CDG & Allies FCT, NOVA University, World CDG Organization and Portuguese Association for CDG).

Disclaimer

The Site cannot and does not contain medical or health advice. The information is provided for general informational and educational purposes only and is not a substitute for professional advice.

Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical or health advice. The use or reliance of any information contained on this site is solely at your own risk.

Follow Us

Like the World CDG Organization Facebook Page. Share the page on your own timeline and tell your friends to share it.
Follow us on Twitter and LinkedIn.
Subscribe to our Youtube channel and invite your friends to subscribe too.

CDG
Congenital Disorders of Glycosylation

Page modified at Monday, July 11, 2022 - 16:45